cholestyramine powder for suspension NDC 71335-2902

NDC codes

FDA NDC Directory

Product NDC (as listed)71335-2902Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71335-2902Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71335-2902-1	71335290201	368.76 g in 1 CAN (71335-2902-1)Marketed from Nov 7, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): cholestyramine powder for suspension
Generic name (nonproprietary): cholestyramine powder for suspension
Active ingredients: Cholestyramine — 4 g/8.78g
Dosage form: Powder, For suspension
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211856
Marketing start: Oct 20, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Bile-acid Binding Activity (Mechanism)
Identifiers: Product ID 71335-2902_311870d0-0a69-4c33-9c1b-467cdb9a1e54SPL ID 311870d0-0a69-4c33-9c1b-467cdb9a1e54SPL set ID 408ad775-9a1b-43cc-b122-226ade73e0c2RxCUI 848943UNII 4B33BGI082
Pharmacologic class: Bile Acid Sequestrant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471335290201 followed by a unit qualifier and the quantity

Package 71335-2902-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 25, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE 1) Cholestyramine for oral suspension, USP powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular di…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211856

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211856
Product	Strength	Form · route	Labeler	Product NDC
cholestyramine powder for suspension	Cholestyramine 4 g/8.78g	Powder, For suspensionOral	Bryant Ranch Prepack	72162-1834
cholestyramine powder for suspension	Cholestyramine 4 g/8.78g	Powder, For suspensionOral	Bryant Ranch Prepack	63629-9196
cholestyramine powder for suspension	Cholestyramine 4 g/8.78g	Powder, For suspensionOral	Ascend Laboratories, LLC	67877-298